CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

Synthetic Biologics

HR Notices From October 8

The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies, institutions nad groiups

WWJ Newsradio 950–10/09/2012

Synthetics Biologics

Synthetic Biologics Developing Monoclonal Antibodies To Treat Acinetobacter Infections

Synthetic Biologics Inc., a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, today announced that it has initiated efforts to develop a monoclonal antibody (mAb) therapy for the treatment of acinetobacter infections.

WWJ Newsradio 950–09/18/2012

Synthetics Biologics

Synthetic Biologics Reports First Quarter 2012 Financial Results

Synthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the three months ended March 31, and summarized operational highlights.

WWJ Newsradio 950–05/15/2012

HR Notices From May 14

Henry Ford Hospital Names Director of New Structural Heart Disease Program:  William W. O’Neill, M.D., has been appointed medical director of the new Center for Structural Heart Disease at Henry Ford Hospital. He will begin […]

WWJ Newsradio 950–05/14/2012

HR Notices From May 11-13

The latest personnel, leadership and boardroom news from Michigan’s technology-focused companies, institutions and groups.

WWJ Newsradio 950–05/13/2012

Synthetics Biologics

Synthetic Biologics Launches Free Investor Relations Mobile Application

Synthetic Biologics Inc. (NYSE Amex: SYN) Thursday announced the release of its investor relations mobile iPhone App, called the “SYN IR” App, now available for free at the Apple App Store on the iPhone or iPad or at http://bit.ly/I9xDpW.

WWJ Newsradio 950–04/26/2012

HR Notices From April 16

The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies, institutions and groups.

WWJ Newsradio 950–04/18/2012

Synthetics Biologics

Synthetic Biologics Announces Completion Of Enrollment In Trial Of MS Drug

Synthetic Biologics Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and medicines for serious illnesses, announced that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics’ proprietary oral formulation of estriol (Trimesta) for the treatment of relapsing-remitting multiple sclerosis.

WWJ Newsradio 950–03/14/2012

Synthetics Biologics

Adeona Becomes Synthetic Biologics, Inc.

Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had received shareholder approval to change its corporate name to Synthetic Biologics Inc.

WWJ Newsradio 950–02/16/2012

Follow

Get every new post delivered to your Inbox.

Join 1,865 other followers